EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases

Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Jianming Lu, Sang-In Kim, Hannah Valencia, Yuman Fong, Yanghee Woo

Molecular Therapy - Oncolytics · 2023-12 · 31 · 100734

DOI: 10.1016/j.omto.2023.100734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy - Oncolytics, 2023-12. Verfasst von Annie Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, City of Hope, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) peritoneal metastasis (PM) is fatal without effective therapy. We investigated CF17, a new replication-competent chimeric poxvirus, against GC cell lines in vitro and PM in an aggressive GCPM mouse model. We performed viral proliferation and cytotoxicity assays on intestinal-type and diffuse-type human GC cell lines following CF17 treatment. At lower MOIs of 0.01, 0.1, there was >80% killing in most cell lines, while in the more aggressive cell lines, killing was seen at higher MOIs of 1.0 and 10.0. We observed reduced peritoneal tumor burden and prolonged survival with intraperitoneal (i.p.) CF17 treatment in nude mice implanted with the resistant GC cell line. At day 91 after treatment, seven of eight mice were alive in the CF17-treated group vs. one of eight mice in the control group. CF17 treatment inhibited ascites formation (0% vs. 62.5% with PBS). Thus, CF17 efficiently infected, replicated in, and killed GC cells in a dose- and time-dependent manner in vitro. In vivo, i.p. CF17 treatment exhibited robust antitumor activity against an aggressive GCPM model to decrease tumor burden, improve survival, and prevent ascites formation. These preclinical results inform the design of future clinical trials of CF17 for peritoneal-directed therapy in GCPM patients.

Schlagwörter

Stichwörter der Autor:innen

CF17gastric cancerimmunotherapymalignant ascitesoncolytic virusesperitoneal metastasisperitoneal-directed therapy

Autor:innen und Institutionen

  • Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, USA.
  • Cancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, USA.

Förderung

  • NCI NIH HHS
  • City of Hope
  • National Institutes of Health
  • National Cancer Institute
  • Department of Surgery

Zitieren

APA

Yang, A., Zhang, Z., Chaurasiya, S., Park, A. K., Lu, J., Kim, S. I., Valencia, H., Fong, Y., & Woo, Y. (2023). Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases. Molecular Therapy - Oncolytics, 31, 100734. https://doi.org/10.1016/j.omto.2023.100734

Vancouver

Yang A, Zhang Z, Chaurasiya S, Park AK, Lu J, Kim SI, et al. Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases. Molecular Therapy - Oncolytics. 2023;31:100734. doi:10.1016/j.omto.2023.100734

BibTeX
@article{Yang2023,
  author = {Yang, Annie and Zhang, Zhifang and Chaurasiya, Shyambabu and Park, Anthony K and Lu, Jianming and Kim, Sang-In and Valencia, Hannah and Fong, Yuman and Woo, Yanghee},
  title = {Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases},
  journal = {Molecular Therapy - Oncolytics},
  year = {2023},
  volume = {31},
  pages = {100734},
  doi = {10.1016/j.omto.2023.100734}
}
Kostenlos starten →